3.94
전일 마감가:
$3.97
열려 있는:
$3.93
하루 거래량:
90,784
Relative Volume:
0.80
시가총액:
$34.04M
수익:
$140.46M
순이익/손실:
$-146.34M
주가수익비율:
-3.1024
EPS:
-1.27
순현금흐름:
$-117.73M
1주 성능:
+0.25%
1개월 성능:
-15.27%
6개월 성능:
-58.37%
1년 성능:
-68.67%
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
명칭
Karyopharm Therapeutics Inc
전화
617-658-0600
주소
85 WELLS AVENUE, NEWTON, MA
KPTI을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
KPTI
Karyopharm Therapeutics Inc
|
3.94 | 34.82M | 140.46M | -146.34M | -117.73M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
![]()
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-16 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-07-11 | 재개 | H.C. Wainwright | Buy |
2023-01-19 | 개시 | Piper Sandler | Overweight |
2022-11-04 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2022-02-09 | 업그레이드 | JP Morgan | Underweight → Neutral |
2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
2021-08-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2021-08-06 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2021-08-06 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2020-07-02 | 개시 | Morgan Stanley | Overweight |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-17 | 다운그레이드 | Wedbush | Outperform → Neutral |
2019-07-23 | 업그레이드 | JP Morgan | Neutral → Overweight |
2019-07-05 | 재확인 | H.C. Wainwright | Buy |
2019-07-05 | 재확인 | Robert W. Baird | Outperform |
2019-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2019-02-28 | 재확인 | BofA/Merrill | Underperform |
2019-02-27 | 다운그레이드 | BofA/Merrill | Neutral → Underperform |
2019-01-03 | 업그레이드 | BofA/Merrill | Underperform → Neutral |
2018-12-03 | 개시 | B. Riley FBR | Buy |
2018-11-09 | 업그레이드 | Wedbush | Neutral → Outperform |
2018-05-24 | 다운그레이드 | Wedbush | Outperform → Neutral |
2018-04-02 | 재개 | Leerink Partners | Outperform |
2017-11-15 | 재개 | H.C. Wainwright | Buy |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2016-09-08 | 재확인 | H.C. Wainwright | Buy |
2016-08-30 | 업그레이드 | Jefferies | Hold → Buy |
2016-08-18 | 개시 | H.C. Wainwright | Buy |
2016-06-28 | 개시 | Robert W. Baird | Outperform |
모두보기
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Earnings Outlook For Karyopharm Therapeutics - 富途牛牛
Visual trend scoring systems applied to Karyopharm Therapeutics Inc.Technical Reversal Setup with Risk Limits - Newser
Automated trading signals detected on Karyopharm Therapeutics Inc.Free Community Strategy With High Win Rate - Newser
Chart based exit strategy for Karyopharm Therapeutics Inc.Secure Entry Point Finder with Analysis - Newser
How moving averages guide Karyopharm Therapeutics Inc. tradingMarket Timing Strategy with Technical Filters - Newser
Karyopharm Therapeutics Inc expected to post a loss of $4.10 a shareEarnings Preview - TradingView
Tick level data insight on Karyopharm Therapeutics Inc. volatilityTechnical Trade Plan with Entry Checklist - Newser
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesFree Weekly Potential Breakout Stock List - Newser
Karyopharm Therapeutics Inc (KPTI) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
What data driven models say about Karyopharm Therapeutics Inc.’s futureBuy Strategy Review With Performance Summary - Newser
Layoff Tracker: 60 Biotech Staff Lose Jobs as Poseida, Alltrna Reduce Workforce - BioSpace
Karyopharm to Report Second Quarter 2025 Financial Results on August 11, 2025 - Eastern Progress
Karyopharm Therapeutics Inc. stock prediction for this weekAI Swing Strategy Signal Forecasting System - Newser
Candlestick signals on Karyopharm Therapeutics Inc. stock todayHigh Reward Picks with Tight Risk Control - Newser
Is a relief rally coming for Karyopharm Therapeutics Inc. holdersFast Entry Strategy with Price Prediction - Newser
Karyopharm to Report Second Quarter 2025 Financial Results on Au - GuruFocus
Will Karyopharm Therapeutics Inc. stock split in the near futureStock Price Prediction Using AI Tools - Newser
Karyopharm Therapeutics Inc. Sees Spike in Bullish Option FlowPattern Alert With ROI Driven Strategy Shared - beatles.ru
Is Karyopharm Therapeutics Inc. a growth stock or a value stockTriple-digit profit margins - Jammu Links News
Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionUnlock real-time trading signals for gains - Jammu Links News
What makes Karyopharm Therapeutics Inc. stock price move sharplyUnlock powerful portfolio management tools - Jammu Links News
How does Karyopharm Therapeutics Inc. compare to its industry peersAchieve impressive returns with smart timing - Jammu Links News
What is the risk reward ratio of investing in Karyopharm Therapeutics Inc. stockBuild a winning portfolio with smart picks - Jammu Links News
Will Karyopharm Therapeutics Inc. see short term momentumFree AI Screening for Swing Trade Picks - Newser
What institutional investors are buying Karyopharm Therapeutics Inc. stockFree Daily Trading Room Entry - Jammu Links News
Should I hold or sell Karyopharm Therapeutics Inc. stock in 2025Overwhelming financial success - Jammu Links News
When is Karyopharm Therapeutics Inc. stock expected to show significant growthCapitalize on fast-moving stock opportunities - Jammu Links News
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Is Karyopharm Therapeutics Inc. stock overvalued or undervaluedRapid portfolio appreciation - Jammu Links News
Why Karyopharm Therapeutics Inc. stock attracts strong analyst attentionEntry Signal Momentum Tracker Review - beatles.ru
Karyopharm's Strategic Use of Inducement Grants to Attract Talent in a Competitive Biotech Landscape - AInvest
Karyopharm Therapeutics Awards 333 Restricted Stock Units to New Employee - AInvest
KARYOPHARM THERAPEUTICS Earnings Preview: Recent $KPTI Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Published on: 2025-07-30 09:02:26 - metal.it
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
What makes Karyopharm Therapeutics Inc. stock attractive to long term investorsGrowth Based Stock Signal Screener Updated - metal.it
Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN
How many analysts rate Karyopharm Therapeutics Inc. as a “Buy”Invest smarter with expert trading signals - Jammu Links News
How strong is Karyopharm Therapeutics Inc. company’s balance sheetPost Market Review For 2025 - Jammu Links News
Has Karyopharm Therapeutics Inc. found a price floorDaily Market Momentum and Pressure Analysis - Newser
Karyopharm Therapeutics Inc (KPTI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):